ES2483124T3 - Composición farmacéutica de nanopartículas magnéticas - Google Patents

Composición farmacéutica de nanopartículas magnéticas Download PDF

Info

Publication number
ES2483124T3
ES2483124T3 ES11159810.8T ES11159810T ES2483124T3 ES 2483124 T3 ES2483124 T3 ES 2483124T3 ES 11159810 T ES11159810 T ES 11159810T ES 2483124 T3 ES2483124 T3 ES 2483124T3
Authority
ES
Spain
Prior art keywords
particles
magnetic
fatty acid
pharmaceutical composition
particle
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES11159810.8T
Other languages
English (en)
Inventor
Eveline Schreiber
Rainer Tietze
Christoph Alexiou
Stefan Lyer
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Friedrich Alexander Univeritaet Erlangen Nuernberg FAU
Universitaetsklinikum Erlangen
Original Assignee
Friedrich Alexander Univeritaet Erlangen Nuernberg FAU
Universitaetsklinikum Erlangen
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Friedrich Alexander Univeritaet Erlangen Nuernberg FAU, Universitaetsklinikum Erlangen filed Critical Friedrich Alexander Univeritaet Erlangen Nuernberg FAU
Application granted granted Critical
Publication of ES2483124T3 publication Critical patent/ES2483124T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/12—Ketones
    • A61K31/122—Ketones having the oxygen directly attached to a ring, e.g. quinones, vitamin K1, anthralin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6921—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere
    • A61K47/6923—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being an inorganic particle, e.g. ceramic particles, silica particles, ferrite or synsorb
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/5123—Organic compounds, e.g. fats, sugars

Abstract

Composición farmacéutica adecuada para la orientación magnética, comprendiendo la composición nanopartículas magnéticas, un medio de dispersión acuoso que presenta un contenido de sólidos de entre 8 y 25 mg/ml, comprendiendo las partículas un núcleo de partícula magnética y un recubrimiento que comprende un ácido graso, en el que el ácido graso es ácido láurico y en el que los núcleos de las partículas se recubren con 25 a 45 partes en peso del ácido graso por cada 100 partes en peso de núcleo de la partícula, en el que el núcleo de las partículas es un óxido de hierro, y en el que las partículas magnéticas comprenden además mitoxantrona, que se adhiere directamente sobre la superficie de los núcleos de las partículas y/o en el interior de un agregado de los núcleos de partícula mediante interacción electrostática

Description

imagen1
imagen2
imagen3
imagen4
imagen5
imagen6
imagen7
imagen8
imagen9
imagen10
imagen11
imagen12
imagen13
imagen14

Claims (1)

  1. imagen1
ES11159810.8T 2011-03-25 2011-03-25 Composición farmacéutica de nanopartículas magnéticas Active ES2483124T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP11159810.8A EP2508171B1 (en) 2011-03-25 2011-03-25 Pharmaceutical magnetic nano-particle composition

Publications (1)

Publication Number Publication Date
ES2483124T3 true ES2483124T3 (es) 2014-08-05

Family

ID=44246365

Family Applications (1)

Application Number Title Priority Date Filing Date
ES11159810.8T Active ES2483124T3 (es) 2011-03-25 2011-03-25 Composición farmacéutica de nanopartículas magnéticas

Country Status (2)

Country Link
EP (1) EP2508171B1 (es)
ES (1) ES2483124T3 (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2823858A1 (en) 2013-07-12 2015-01-14 Brossel, Rémy System generating a constraint field, and medical device implementing the same

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW334434B (en) 1995-05-16 1998-06-21 Kanebo Ltd Novel quinazoline compound and anti-tumor agent
EP0971692B1 (de) * 1997-03-07 2003-03-05 Max-Delbrück-Centrum Für Molekulare Medizin Spezifische magnetosomen, verfahren zu ihrer herstellung und ihre verwendung
DE10059151C2 (de) * 2000-11-29 2003-10-16 Christoph Alexiou Magnetische Partikel zur zielgerichteten regionalen Therapie und Verwendung derselben
AU2009346580B2 (en) * 2009-05-21 2014-01-23 Institute Of Life Sciences Water dispersible glyceryl monooleate magnetic nanoparticle formulation
US8383085B2 (en) * 2009-05-29 2013-02-26 University Of Manitoba Methods of making iron-containing nanoparticles

Also Published As

Publication number Publication date
EP2508171A1 (en) 2012-10-10
EP2508171B1 (en) 2014-05-07

Similar Documents

Publication Publication Date Title
BR112015014831A2 (pt) partículas anidras de pó a líquido
BR112017012363A8 (pt) Microcápsulas revestidas, seu uso e produto de consumo que as compreende
AR063366A1 (es) Suspensiones farmaceuticas acuosas que contienen rebamipide y su proceso de fabricacion
Besic Gyenge et al. Uptake and fate of surface modified silica nanoparticles in head and neck squamous cell carcinoma
JP2016531901A5 (es)
CO6561827A2 (es) Nullelementos de seguridad y metodos y aparatos para su fabricación
BR112015012547A2 (pt) composições de prostaciclina e métodos de sua utilização
BR112015000017A2 (pt) partículas poliméricas e seu uso
BRPI0801675A2 (pt) partÍculas de pigmento em nanoescala de quinacridona
JP2009098257A5 (es)
ECSP14009999A (es) Derivados de dihidro-benzo-oxazina y dihidro-pirido-oxazina
JP2014526519A5 (es)
PE20142387A1 (es) Extintor y medio de extintor
ES2483124T3 (es) Composición farmacéutica de nanopartículas magnéticas
BR112014019157A8 (pt) Meio de ligação sintético para cultura de célula
CL2014002865A1 (es) Aparato para la separación con poco uso de recursos de partículas magnéticas a partir de particulas no magnéticas.
BR112016027653A2 (pt) Uso de uma partícula para absorver e reter compostos odoríferosos
AR086895A1 (es) Piperidinas sustituidas moduladoras de receptores gpr119, composiciones farmaceuticas que las contienen y uso de las mismas para el tratamiento de la diabetes, dislipidemias y obesidad
AR097739A1 (es) Imidazo[1,2-a]piridina-7-aminas
AR083408A1 (es) Particulas detergentes para el lavado de la ropa
BR112015025601A2 (pt) pesos de balanceamento com incrustação ferromagnética
BR112014030452A2 (pt) processo para a produção de meios de cultura de células
ES2559802T3 (es) Dispositivo de ayuda a la liberación de gotas de un líquido contenido en el interior de un pulverizador y pulverizador equipado con un dispositivo de este tipo
BR112015030307A2 (pt) composto magnético dendrímero, método para preparação do composto magnético dendrímero, uso do composto magnético dendrímero e lubrificante
UY35824A (es) Preparación farmacéutica y forma de su producción y uso